Finding Relief from Opioid-Induced Constipation: Emerging Therapies for Individualized Management

Finding Relief from Opioid-Induced Constipation: Emerging Therapies for Individualized Management

On-Demand Webcast
Faculty

Jeffrey Gudin, MD
Director, Pain Management and Palliative Care
Englewood Hospital and Medical Center
Englewood, New Jersey

Intended Learners

This live activity is designed for primary care physicians and pain professionals who manage patients with chronic pain and OIC.

Learning Objectives

After completing this activity, participants should be able to:

  • Recognize the prevalence, burden, and barriers to care faced by chronic pain patients with OIC
  • Discuss  the  latest  criteria  for  the  screening  and  diagnosis  of  OIC  in  patients  with  chronic  pain managed by opioids
  • Evaluate the  full  OIC  treatment  armamentarium—including  emerging  targeted  therapies—in terms of mechanism of action, safety, and efficacy
  • Develop  tailored  treatment  plans  that  apply  the  latest  consensus  recommendations  and prescription therapies to effectively manage OIC
Activity Overview

This on-demand webcast is available with synchronized slides and audio.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 7-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

Release Date: October 31, 2017
Expiration Date: October 31, 2018
Estimated time to complete: 0.5 hour

There is no fee associated with this activity.

For questions regarding this educational activity, please call 609-371-1137.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring webcast.

ACPE Credit Policy
Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from NACCME.com after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.


Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Accreditation

In support of improving patient care, North American Center for Continuing Medical Education, LLC (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CME

NACCME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

CNE

This continuing nursing education activity awards .5 contact hour.

Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.

CPE

The following UAN is approved for 0.5 contact hour (0.05 CEU) of continuing pharmacy education:  0276-0000-17-121-H01-P

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Senior Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Clinical Reviewer

Independent Clinical Reviewer: David Walsworth, MD, FAAFP, Associate Professor of Family Medicine, Department of Family Medicine, College of Human Medicine, Michigan State University, Associate Chair for Clinical Affairs, Department of Family Medicine, College of Human Medicine, Michigan State University, East Lansing, Michigan

Nurse Planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California

Planning Committee

The planning committee comprises Jeffrey Gudin, MD, Susie Seaman, NP, David Walsworth, MD, FAAFP; and Donna Brophy, MaryEllen Fama, Mary Johnson, Michelle Montgomery, Randy Robbin, and John Savage, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Gudin: Speakers’ Bureau - Salix, Collegium, Depomed, Purdue, BDSI, Daiichi Sankyo, Teva, AZ; Consultant - Quest Diagnostics, Inspirion, Nektar,Kempharm, Egalet, Scilex, Zogenix, Insys

Ms. Seaman: Advisory Board – MoInlycke Health Care

Dr. Walsworth and Ms. Brophy, Ms. Fama, Ms. Johnson, Ms. Montgomery, Mr. Robbin, and Mr. Savagehave disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty has disclosed that no off-label/unapproved uses of drugs and/or devices will be discussed during this presentation.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2017 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Provided by North American Center for Continuing Medical Education, LLC, An HMP Communications Holdings Company

Grant Support

Supported by an educational grant from Salix Pharmaceuticals, Inc., A Division of Valeant Pharmaceuticals North America LLC and Consultant, a registered trademark of HMP Communications.